How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype

Clinics in Chest Medicine

Volumn 35, Issue 1, 2014, Pages 203-217

  Giembycz, Mark A ^a   Newton, Robert ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acute exacerbations; Combination therapies; COPD phenotypes; Gene transactivation; Phosphodiesterase 4 inhibitors; Roflumilast

Indexed keywords

ACUTE EXACERBATIONS; COMBINATION THERAPIES; COPD PHENOTYPES; GENE TRANSACTIVATION; PHOSPHODIESTERASE 4 INHIBITORS; ROFLUMILAST;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; AMINOPYRIDINES; BENZAMIDES; CYCLOPROPANES; DRUG THERAPY, COMBINATION; HUMANS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84893811262     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.007     Document Type: Review

References (138)

1. Pauwels R.A., Buist A.S., Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
2. Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004, 364:709-721.
3. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. NEngl J Med 2004, 350:2645-2653.
4. Laumbach R.J., Kipen H.M. Respiratory health effects of air pollution: update on biomass smoke and traffic pollution. JAllergy Clin Immunol 2012, 129:3-11.
5. Walter R., Gottlieb D.J., O'Connor G.T. Environmental and genetic risk factors and gene-environment interactions in the pathogenesis of chronic obstructive lung disease. Environ Health Perspect 2000, 108(Suppl 4):733-742.
6. Kleeberger S.R., Cho H.Y. Gene-environment interactions in environmental lung diseases. Novartis Found Symp 2008, 293:168-178.
7. Caramori G., Adcock I. Gene-environment interactions in the development of chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 2006, 6:323-328.
8. Kleeberger S.R., Peden D. Gene-environment interactions in asthma and other respiratory diseases. Annu Rev Med 2005, 56:383-400.
9. Rennard S.I., Vestbo J. The many "small COPDs": COPD should be an orphan disease. Chest 2008, 134:623-627.
10. Miravitlles M., Soler-Cataluna J.J., Calle M., et al. Anew approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013, 22:117-121.
11. Miravitlles M., Jose Soler-Cataluna J., Calle M., et al. Treatment of COPD by clinical phenotypes. Putting old evidence into clinical practice. Eur Respir J 2013, 41(6):1252-1256.
12. Perera W.R., Hurst J.R., Wilkinson T.M., et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534.
13. Calverley P.M., Rabe K.F., Goehring U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
14. Wedzicha1 J.A., Rabe K.F., Martinez F.J., et al. Efficacy of roflumilast in the chronic obstructive pulmonary disease frequent exacerbator phenotype. Chest 2012, 143(5):1302-1311.
15. Butcher R.W., Sutherland E.W. Adenosine 3',5'-phosphatein biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. JBiol Chem 1962, 237:1244-1250.
16. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006, 58:488-520.
17. Dastidar S.G., Rajagopal D., Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007, 8:364-372.
18. Hatzelmann A., Morcillo E.J., Lungarella G., et al. The preclinical pharmacology of roflumilast - a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2010, 23:235-256.
19. Torphy T.J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
20. Oba Y., Lone N.A. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Ther Adv Respir Dis 2013, 7:13-24.
21. Giembycz M.A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005, 5:238-244.
22. Giembycz M.A. An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol 2006, 62:138-152.
23. Giembycz M.A., Field S.K. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 2010, 4:147-158.
24. Gross N.J., Giembycz M.A., Rennard S.I. Treatment of chronic obstructive pulmonary disease with roflumilast - a new phosphodiesterase 4 inhibitor. COPD 2010, 7:141-153.
25. Field S.K. Roflumilast, a novel phosphodiesterase 4 inhibitor, for COPD patients with a history of exacerbations. Clin Med Insights Circ Respir Pulm Med 2011, 5:57-70.
26. Cazzola M., Picciolo S., Matera M.G. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials. Expert Opin Pharmacother 2010, 11:441-449.
27. Antoniu S.A. New therapeutic options in the management of COPD - focus on roflumilast. Int J Chron Obstruct Pulmon Dis 2011, 6:147-155.
28. Rennard S.I., Calverley P.M., Goehring U.M., et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
29. 2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, (9). CD006829.
30. Calverley P.M., Martinez F.J., Fabbri L.M., et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012, 7:375-382.
31. O'Donnell D.E., Aaron S., Bourbeau J., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007, 14(Suppl B):5B-32B.
32. Brassard P., Suissa S., Kezouh A., et al. Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011, 183:675-678.
33. Ernst P., Gonzalez A.V., Brassard P., et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176:162-166.
34. Newton R., Leigh R., Giembycz M.A. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 2010, 125:286-327.
35. Surjit M., Ganti K.P., Mukherji A., et al. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011, 145:224-241.
36. Clark A.R. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 2007, 275:79-97.
37. King E.M., Chivers J.E., Rider C.F., et al. Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One 2013, 8:e53936.
38. Scheinman R.I., Cogswell P.C., Lofquist A.K., et al. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995, 270:283-286.
39. Auphan N., DiDonato J.A., Rosette C., et al. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995, 270:286-290.
40. Kelly M.M., King E.M., Rider C.F., et al. Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide. Br J Pharmacol 2012, 165:1737-1747.
41. 2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 2008, 73:201-214.
42. 2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002, 360:1293-1299.
43. Rangarajan P.N., Umesono K., Evans R.M. Modulation of glucocorticoid receptor function by protein kinase A. Mol Endocrinol 1992, 6:1451-1457.
44. Miller A.H., Vogt G.J., Pearce B.D. The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 2002, 27:939-948.
45. Wilson S.M., Shen P., Rider C.F., et al. Selective prostacyclin receptor agonism augments glucocorticoid-induced gene expression in human bronchial epithelial cells. JImmunol 2009, 183:6788-6799.
46. Moodley T., Wilson S.M., Joshi T., et al. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe COPD. Mol Pharmacol 2013, 83:894-906.
47. 2B- and glucocorticoid receptors in human airway epithelial cells cooperatively induces genes with anti-inflammatory potential: a novel approach to treat COPD. JPharmacol Exp Ther 2013, 346(3):473-485.
48. 2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010, (5). CD005535.
49. Frois C., Wu E.Q., Ray S., et al. Inhaled corticosteroids or long-acting β-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther 2009, 31:2779-2803.
50. Pauwels R.A., Lofdahl C.G., Postma D.S., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. NEngl J Med 1997, 337:1405-1411.
51. Shrewsbury S., Pyke S., Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000, 320:1368-1373.
52. Plint A.C., Johnson D.W., Patel H., et al. Epinephrine and dexamethasone in children with bronchiolitis. NEngl J Med 2009, 360:2079-2089.
53. Kuyucu S., Unal S., Kuyucu N., et al. Additive effects of dexamethasone in nebulized salbutamol or L-epinephrine treated infants with acute bronchiolitis. Pediatr Int 2004, 46:539-544.
54. Su A.I., Wiltshire T., Batalov S., et al. Agene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004, 101:6062-6067.
55. Pujols L., Mullol J., Roca-Ferrer J., et al. Expression of glucocorticoid receptor α- and β-isoforms in human cells and tissues. Am J Physiol Cell Physiol 2002, 283:C1324-C1331.
56. Plumb J., Gaffey K., Kane B., et al. Reduced glucocorticoid receptor expression and function in airway neutrophils. Int Immunopharmacol 2012, 12:26-33.
57. Miller A.H., Spencer R.L., Pearce B.D., et al. Glucocorticoid receptors are differentially expressed in the cells and tissues of the immune system. Cell Immunol 1998, 186:45-54.
58. Adcock I.M., Gilbey T., Gelder C.M., et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am J Respir Crit Care Med 1996, 154:771-782.
59. Schleimer R.P. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis 1990, 141:S59-S69.
60. 2-agonists on resident and infiltrating inflammatory cells. JAllergy Clin Immunol 2002, 110:S282-S290.
61. 2-mediated adenylyl cyclase activity in human airway epithelial cells. Am J Respir Cell Mol Biol 1994, 11:496-505.
62. Kelsen S.G., Higgins N.C., Zhou S., et al. Expression and function of the β-adrenergic receptor coupled-adenylyl cyclase system on human airway epithelial cells. Am J Respir Crit Care Med 1995, 152:1774-1783.
63. 2-adrenergic receptors on human alveolar macrophages. Am Rev Respir Dis 1989, 139:552-555.
64. 2-Adrenergic receptors on eosinophils. Binding and functional studies. Am Rev Respir Dis 1990, 141:1446-1452.
65. 3H]-dihydroalprenolol to human polymorphonuclear cell particulates. JLab Clin Med 1978, 92:613-618.
66. Martinsson A., Larsson K., Hjemdahl P. Studies invivo and invitro of terbutaline-induced β-adrenoceptor desensitization in healthy subjects. Clin Sci (Lond) 1987, 72:47-54.
67. Furchgott R.F. The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res 1966, 3:21-55.
68. Rabe K.F., Giembycz M.A., Dent G., et al. Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol 1993, 231:305-308.
69. Munoz N.M., Rabe K.F., Vita A.J., et al. Paradoxical blockade of β-adrenergically-mediated inhibition of stimulated eosinophil secretion by salmeterol. JPharmacol Exp Ther 1995, 273:850-854.
70. Newton R. Molecular mechanisms of glucocorticoid action: what is important?. Thorax 2000, 55:603-613.
71. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
72. Clark A.R., Martins J.R., Tchen C.R. Role of dual specificity phosphatases in biological responses to glucocorticoids. JBiol Chem 2008, 283:25765-25769.
73. 2-agonists upregulate mitogen-activated protein kinase phosphatase 1: invitro mechanisms. Br J Pharmacol 2012, 166:2049-2059.
74. Quante T., Ng Y.C., Ramsay E.E., et al. Corticosteroids reduce IL-6 in ASM cells via up-regulation of MKP-1. Am J Respir Cell Mol Biol 2008, 39:208-217.
75. Lee J., Komatsu K., Lee B.C., et al. Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. JBiol Chem 2012, 287:22799-22811.
76. Issa R., Xie S., Khorasani N., et al. Corticosteroid inhibition of growth-related oncogene protein-alpha via mitogen-activated kinase phosphatase-1 in airway smooth muscle cells. JImmunol 2007, 178:7366-7375.
77. King E.M., Holden N.S., Gong W., et al. Inhibition of NF-κB-dependent transcription by MKP-1: transcriptional repression by glucocorticoids occurring via p38 MAPK. JBiol Chem 2009, 284:26803-26815.
78. Diefenbacher M., Sekula S., Heilbock C., et al. Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1. Mol Endocrinol 2008, 22:1767-1780.
79. Lasa M., Abraham S.M., Boucheron C., et al. Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38. Mol Cell Biol 2002, 22:7802-7811.
80. Abraham S.M., Lawrence T., Kleiman A., et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. JExp Med 2006, 203:1883-1889.
81. Li F., Zhang M., Hussain F., et al. Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids. Eur Respir J 2011, 37:933-942.
82. 2-agonists increase fluticasone propionate-induced mitogen-activated protein kinase phosphatase 1 (MKP-1) in airway smooth muscle cells. PLoS One 2013, 8:e59635.
83. Kwak S.P., Hakes D.J., Martell K.J., et al. Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene. JBiol Chem 1994, 269:3596-3604.
84. Cho I.J., Woo N.R., Shin I.C., et al. H89, an inhibitor of PKA and MSK, inhibits cyclic-AMP response element binding protein-mediated MAPK phosphatase-1 induction by lipopolysaccharide. Inflamm Res 2009, 58:863-872.
85. Innes A.L., Woodruff P.G., Ferrando R.E., et al. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006, 130:1102-1108.
86. Caramori G., Casolari P., Di Gregorio C., et al. MUC5AC expression is increased in bronchial submucosal glands of stable COPD patients. Histopathology 2009, 55:321-331.
87. Dohrman A., Miyata S., Gallup M., et al. Mucin gene (MUC2 and MUC5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim Biophys Acta 1998, 1406:251-259.
88. Ayroldi E., Riccardi C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB J 2009, 23:3649-3658.
89. Mittelstadt P.R., Ashwell J.D. Inhibition of AP-1 by the glucocorticoid-inducible protein GILZ. JBiol Chem 2001, 276:29603-29610.
90. Godot V., Garcia G., Capel F., et al. Dexamethasone and IL-10 stimulate glucocorticoid-induced leucine zipper synthesis by human mast cells. Allergy 2006, 61:886-890.
91. Ayroldi E., Migliorati G., Bruscoli S., et al. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. Blood 2001, 98:743-753.
92. Di Marco B., Massetti M., Bruscoli S., et al. Glucocorticoid-induced leucine zipper (GILZ)/NF-κB interaction: role of GILZ homo-dimerization and C-terminal domain. Nucleic Acids Res 2007, 35:517-528.
93. Ayroldi E., Zollo O., Macchiarulo A., et al. Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1. Mol Cell Biol 2002, 22:7929-7941.
94. Eddleston J., Herschbach J., Wagelie-Steffen A.L., et al. The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. JAllergy Clin Immunol 2007, 119:115-122.
95. Heximer S.P., Watson N., Linder M.E., et al. RGS2/G0S8 is a selective inhibitor of Gqα function. Proc Natl Acad Sci U S A 1997, 94:14389-14393.
96. 2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids. Proc Natl Acad Sci U S A 2011, 108:19713-19718.
97. Liu C., Li Q., Zhou X., et al. Regulator of G-protein signaling 2 inhibits acid-induced mucin5AC hypersecretion in human airway epithelial cells. Respir Physiol Neurobiol 2013, 185:265-271.
98. Snelgrove R.J., Goulding J., Didierlaurent A.M., et al. Acritical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008, 9:1074-1083.
99. Wang Z.Q., Xing W.M., Fan H.H., et al. The novel lipopolysaccharide-binding protein CRISPLD2 is a critical serum protein to regulate endotoxin function. JImmunol 2009, 183:6646-6656.
100. Kaplan F., Ledoux P., Kassamali F.Q., et al. Anovel developmentally regulated gene in lung mesenchyme: homology to a tumor-derived trypsin inhibitor. Am J Physiol 1999, 276:L1027-L1036.
101. kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol 1999, 13:1811-1822.
102. 2-adrenoceptor agonists synergize to inhibit airway smooth muscle remodeling. JPharmacol Exp Ther 2012, 342:780-787.
103. 2-terminal kinase/stress-activated protein kinase. JBiol Chem 2003, 278:48092-48098.
104. Yoshimura A., Naka T., Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007, 7:454-465.
105. Milne G.R., Palmer T.M., Yarwood S.J. Novel control of cAMP-regulated transcription in vascular endothelial cells. Biochem Soc Trans 2012, 40:1-5.
106. Nasreen N., Khodayari N., Sukka-Ganesh B., et al. Fluticasone propionate and salmeterol combination induces SOCS-3 expression in airway epithelial cells. Int Immunopharmacol 2012, 12:217-225.
107. Liang R., Zhang W., Song Y.M. Levels of leptin and IL-6 in lungs and blood are associated with the severity of chronic obstructive pulmonary disease in patients and rat models. Mol Med Rep 2013, 7:1470-1476.
108. Barnes P.J. The cytokine network in COPD. Am J Respir Cell Mol Biol 2009, 41:631-638.
109. Hershko A., Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-479.
110. Jono H., Lim J.H., Chen L.F., et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-κB: evidence for a novel inducible autoregulatory feedback pathway. JBiol Chem 2004, 279:36171-36174.
111. Reiley W., Zhang M., Sun S.C. Negative regulation of JNK signaling by the tumor suppressor CYLD. JBiol Chem 2004, 279:55161-55167.
112. Lim J.H., Jono H., Komatsu K., et al. CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun 2012, 3:771.
113. Sun S.C. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ 2010, 17:25-34.
114. Lim J.H., Ha U.H., Woo C.H., et al. CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cell Microbiol 2008, 10:2247-2256.
115. Lim J.H., Jono H., Koga T., et al. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2007, 2:e1032.
116. Lim J.H., Stirling B., Derry J., et al. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007, 27:349-360.
117. Komatsu K., Lee J.Y., Miyata M., et al. Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun 2013, 4:1684.
118. Anderson P. Post-transcriptional control of cytokine production. Nat Immunol 2008, 9:353-359.
119. King E.M., Kaur M., Gong W., et al. Regulation of tristetraprolin expression by interleukin-1β and dexamethasone in human pulmonary epithelial cells: roles for nuclear factor-κB and p38 mitogen-activated protein kinase. JPharmacol Exp Ther 2009, 330:575-585.
120. Smoak K., Cidlowski J.A. Glucocorticoids regulate tristetraprolin synthesis and post-transcriptionally regulate tumor necrosis factor α inflammatory signaling. Mol Cell Biol 2006, 26:9126-9135.
121. Ishmael F.T., Fang X., Galdiero M.R., et al. Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. JImmunol 2008, 180:8342-8353.
122. Jalonen U., Leppanen T., Kankaanranta H., et al. Salbutamol increases tristetraprolin expression in macrophages. Life Sci 2007, 81:1651-1658.
123. 2-adrenoceptor agonists. JPharmacol Exp Ther 2011, 338:860-869.
124. Salem S., Harris T., Mok J.S., et al. Transforming growth factor-β impairs glucocorticoid activity in the A549 lung adenocarcinoma cell line. Br J Pharmacol 2012, 166:2036-2048.
125. Hinzey A., Alexander J., Corry J., et al. Respiratory syncytial virus represses glucocorticoid receptor-mediated gene activation. Endocrinology 2011, 152:483-494.
126. 2-adrenoceptor agonists. Eur J Pharmacol 2013, 708:60-67.
127. Xie Y., Jiang H., Nguyen H., et al. Regulator of G protein signaling 2 is a key modulator of airway hyperresponsiveness. JAllergy Clin Immunol 2012, 130:968-976.
128. 2-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action. Br J Pharmacol 2010, 160:410-420.
129. Manolitsas N.D., Wang J., Devalia J.L., et al. Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am J Respir Crit Care Med 1995, 151:1925-1930.
130. Gauvreau G.M., Jordana M., Watson R.M., et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997, 156:1738-1745.
131. 2-adrenoceptor signalling in the airways. Eur Respir J 2006, 27:1286-1306.
132. Lecuona E., Ridge K., Pesce L., et al. The GTP-binding protein RhoA mediates Na, K-ATPase exocytosis in alveolar epithelial cells. Mol Biol Cell 2003, 14:3888-3897.
133. 2-AR function in airway smooth muscle by Gi-mediated counterregulation in transgenic mice over-expressing type 5 adenylyl cyclase. Am J Physiol Lung Cell Mol Physiol 2011, 300:L472-L478.
134. Giembycz M.A., Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol 2011, 204:415-446.
135. Giembycz M.A. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br J Pharmacol 2008, 155:288-290.
136. Burgin A.B., Magnusson O.T., Singh J., et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010, 28:63-70.
137. 2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD. Bioorg Med Chem Lett 2012, 22:1523-1526.
138. 2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD. Bioorg Med Chem Lett 2013, 23:1548-1552.